ANIP
ANI Pharmaceuticals, Inc. · Healthcare
79.83
3.41%(+2.63)
Market OpenLast Updated: — ET
52W L: $56.7152W H: $99.50
$79.76
CHG+5.26 (+7.06%)
H$81.14
L$70.17
VOL5.6M
ANIP (1h)
ANI Pharmaceuticals, Inc. · Healthcare
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
PRINCETON, N.J., April 07, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced publication of the results from the NEW DAY clinical trial involving ILUVIEN® (fluocinolone acetonide intravitreal implant), 0.19 mg (ILUVIEN) for use in appropriate patients with diabetic macular edema in Ophthalmology, the journal of the American Academy of Ophthalmology. The company previously announced results from the NEW DAY trial in July 2025. ILUVIEN is a corticosteroid indicated for the treatment of diabetic macular edema (DME) in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure.
ANI Pharmaceuticals recently offered up solid FY26 guidance with 15% non-GAAP EPS growth and strong momentum from Cortrophin Gel. ANIP's increasing reliance on Cortrophin Gel, projected to reach 52% of FY26 revenue, is offset by patent protection and a complex formulation. The company's balance sheet remains solid, supporting ongoing investments in rare disease expansion and 10–15 annual generic launches.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
The mean of analysts' price targets for ANI (ANIP) points to a 43.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
ANIP eyes 2026 pivot as Rare Disease targets 60% of sales, with Cortrophin growth, gout sales force expansion, and retina rebound shaping momentum.
Rowland Thomas Andrew
officer: SVP, HEAD - ESTABLISHED BRANDS
4,772 SH @ $74.91
2026-03-11
Mutz Christopher
officer: HEAD OF RARE DISEASE
3,162 SH @ $71.64
2026-03-13
Cook Meredith
officer: SR. VP, GENERAL COUNSEL & SEC.
500 SH @ $72.62
2026-03-13
Mutz Christopher
officer: HEAD OF RARE DISEASE
2,121 SH @ $74.22
2026-03-06
Mutz Christopher
officer: HEAD OF RARE DISEASE
3,314 SH @ $74.04
2026-03-07
Mutz Christopher
officer: HEAD OF RARE DISEASE
3,602 SH @ $74.18
2026-03-09
Lalwani Nikhil
director, officer: PRESIDENT & CEO
17,060 SH @ $74.04
2026-03-07
Gutwerg Ori
officer: SVP, GENERICS
3,314 SH @ $74.04
2026-03-07